Palatin Technologies Enters Warrant Inducement Agreement With Institutional Investor To Exercise 3,233,277 Shares Issued In November 2022 And October 2023, Raising $6.1M

Palatin Technologies Enters Warrant Inducement Agreement With Institutional Investor To Exercise 3,233,277 Shares Issued In November 2022 And October 2023, Raising $6.1M

BenzingaJun 21 20:04

Palatin Announces Exercise of Warrants for Approximately $6.1 Million Gross Proceeds

Palatin Technologies, Inc. (NYSE American: PTN) ("Palatin" or the "Company"), a biopharmaceutical company developing first-in-class medicines based...

PR NewswireJun 21 20:00

Express News | Palatin Technologies: Potential Phase 3 Clinical Study in Ed Patients Who Do Not Respond to Pde5I Monotherapy to Start in H1 2025

BreakingsJun 20 19:31

Express News | Palatin Announces the Initiation of a Phase 2 Clinical Study of Bremelanotide Co-Administered With a Pde5I for the Treatment of Erectile Dysfunction (Ed)

BreakingsJun 20 19:30

Sector Update: Health Care Stocks Ease Late Afternoon

Health care stocks were softer late Wednesday afternoon, with the NYSE Health Care Index decreasing 0.3% and the Health Care Select Sector SPDR Fund (XLV) down 0.1%. The iShares Biotechnology ETF (IBB

MT NewswiresJun 13 04:02

Palatin Technologies Starts Phase 2 of Obesity Treatment Study

Palatin Technologies (PTN) said Wednesday it has started a phase 2 clinical trial to assess the safety and efficacy of bremelanotide, a melanocortin 4 receptor agonist, administered alongside tirzepat

MT NewswiresJun 13 02:16